Shareholders Approve Warrants Enabling Nearly 100% Potential Dilution

summarizeSummary

Akari Therapeutics shareholders approved the exercisability of warrants, potentially leading to nearly 100% dilution of outstanding shares, following prior proxy statements.

check_boxKey Events

• Shareholder Approval for Warrant Exercisability

  Shareholders approved the exercisability of Series G, Placement Agent, Pre-Funded, and Note Exchange Warrants at a Special General Meeting held on March 2, 2026.

• Significant Potential Dilution

  The approved warrants represent the potential issuance of approximately 44.03 million ADSs. If all these shares were issued, it would result in approximately 96.16% dilution relative to the current outstanding ADSs.

• Finalizes Prior Disclosures

  This vote concludes the process outlined in the DEF 14A and PRE 14A filings from January and February 2026, which sought shareholder approval for these highly dilutive warrants.

• Enables Capital Raising

  The approval enables the company to raise capital through the exercise of these warrants, providing a funding mechanism but at the cost of substantial dilution for current investors.

auto_awesomeAnalysis

Akari Therapeutics shareholders have approved the exercisability of various warrants, which, if fully exercised, could nearly double the company's outstanding shares. This approval finalizes the process initiated by previous proxy filings and allows for the issuance of over 44 million American Depositary Shares (ADSs). While this provides a mechanism for the company to raise capital, the significant potential dilution poses a substantial risk to existing shareholders, especially for a micro-cap company.